**Vaccine Breakthrough:** Pfizer’s Abrysvo Protects High-Risk Adults Against Respiratory Syncytial Virus – Find Out How!
New York, NY – Pfizer announced on Tuesday that their vaccine has shown promising results in protecting high-risk adults aged 18 to 59 from respiratory syncytial virus (RSV). The vaccine, known as Abrysvo, has been found to be effective for this age group, potentially offering a wider population protection against RSV. Previously approved for adults 60 and older, as well as expectant mothers, Abrysvo now holds potential for younger, high-risk adults who are vulnerable to …